Excipients

AMRI to Develop and Manufacture Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine

February 25, 2021

The company will join the network of approved manufacturers of the lipid excipients.

Helena Offers Polymer Solution to Global Cold Chain Issues for COVID-19 Vaccines, Biologics, and Therapeutics

December 16, 2020

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

Evonik to Acquire Birmingham-Based LACTEL Absorbable Polymers from DURECT Corporation

December 10, 2020

With the acquisition, Evonik will expand its life science division and its portfolio of functional excipients and biomaterials.

Understanding Excipient Quality and Impact on Formulation

November 04, 2020

At the 2020 Bio/Pharma Virtual Congress, experts discuss the importance of characterizing excipients to ensure quality, safety, and effective performance.

CordenPharma Expands Lipid Supply for Moderna

June 04, 2020

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

USP Offers Support for COVID-19 Drug Developers

March 19, 2020

USP technical advisors will offer assistance to drug developers to ensure material quality and testing.

MilliporeSigma and ReForm Collaborate on Excipient Commercialization

February 13, 2020

The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.

Low-Impurity Sucrose Lowers Risk of Protein Instability in Biopharmaceutical Formulation

November 20, 2019

A new sucrose product from MilliporeSigma has reduced nanoparticle impurities.

LBB Specialties Enters into Strategic Partnership for Excipient Product Distribution

August 29, 2019

LBB Specialties and Meggle Excipients & Technology will work to distribute excipient products to companies in the American pharmaceutical and nutraceutical industries.

Ajinomoto Bio-Pharma to Acquire Joint Venture Granules OmniChem in India

August 29, 2019

The transaction will reach completion during the fourth quarter of 2019.